Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selecting initial therapy for invasive breast cancer.

M E Lippman1

  • 1Medical Breast Cancer Section, National Cancer Institute, Bethesda, Maryland 20892.

Cancer
|October 15, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer.

Breast cancer research and treatment·2019
Same author

Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome.

Breast cancer research and treatment·2017
Same author

Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis.

Oncogene·2016
Same author

Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression.

Oncogene·2015
Same author

CD44 is prognostic for overall survival in the NCI randomized trial on breast conservation with 25 year follow-up.

Breast cancer research and treatment·2013
Same author

Correlation of GREB1 mRNA with protein expression in breast cancer: validation of a novel GREB1 monoclonal antibody.

Breast cancer research and treatment·2009

Choosing the best localized breast cancer therapy remains debated. This review examines prognostic variables and key trials like NSABP B-06 to guide rational treatment decisions for early-stage breast cancer.

Area of Science:

  • Oncology
  • Clinical Trials
  • Breast Cancer Research

Background:

  • Therapeutic decisions for localized breast cancer lack consensus.
  • Published clinical data often presents conflicting findings, polarizing expert opinions.
  • Prognostic variables can significantly influence study outcomes, leading to institutional differences.

Purpose of the Study:

  • To critically evaluate factors influencing localized breast cancer treatment outcomes.
  • To review prospectively randomized trials that define acceptable therapeutic limits.
  • To provide a framework for rational treatment selection in Stage I and II breast cancer.

Main Methods:

  • Detailed analysis of clinical, pathologic, biochemical, and kinetic prognostic variables.
  • Review of landmark prospectively randomized trials, including NSABP B-06, Milan Cancer Institute trial, and NCI investigations.

Related Experiment Videos

  • Assessment of trial limitations and their impact on therapeutic recommendations.

    • Main Results:

    • Identified numerous variables that can confound interpretation of treatment efficacy.
    • Highlighted discrepancies in results from institutions using similar treatment plans.
    • Emphasized the critical role of well-designed randomized trials in establishing evidence-based guidelines.

    Conclusions:

    • A comprehensive understanding of prognostic factors is essential for interpreting breast cancer treatment data.
    • Randomized trials provide crucial evidence but have inherent limitations.
    • Informed selection of primary therapy for Stage I and II breast cancer requires careful consideration of all available evidence.